盐酸氨溴索联合头孢哌酮舒巴坦钠治疗重症肺炎患者的效果

Effects of Ambroxol hydrochloride combined with Cefoperazone Sulbactam sodium in treatment of severe pneumonia patients

目的:观察盐酸氨溴索联合头孢哌酮舒巴坦钠治疗重症肺炎患者的效果。方法:选取72例重症肺炎患者为研究对象,按照随机数字表法分为对照组和研究组各36例。对照组采用头孢哌酮舒巴坦钠治疗,研究组在对照组基础上联合盐酸氨溴索治疗,比较两组临床疗效、临床症状消失时间、治疗前后炎性因子[C反应蛋白(CRP)、白细胞介素(IL)-6、IL-10]水平、肺功能指标[第1秒呼气容积(FEV_(1))、FEV_(1)/FVC、用力呼气流量(FEF75%)]水平及不良反应发生率。结果:研究组治疗总有效率为97.22%,高于对照组的66.67%,差异有统计学意义(P<0.05);治疗后,研究组高热、咳嗽、咳痰及肺啰音等临床症状消失时间均短于对照组,差异有统计学意义(P>0.05);研究组CRP、IL-6水平均低于对照组,IL-10水平高于对照组,差异有统计学意义(P<0.05);研究组FEV_(1)、FEV_(1)/FVC、FEF75%水平均高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:盐酸氨溴索联合头孢哌酮舒巴坦钠治疗重症肺炎患者,可提高临床疗效,缩短临床症状消失时间,降低炎性因子水平,提高肺功能指标水平,且安全性较高,其效果优于单纯头孢哌酮舒巴坦钠治疗。

Objective:To observe effects of Ambroxol hydrochloride combined with Cefoperazone Sulbactam sodium in treatment of severe pneumonia patients.Methods:72 patients with severe pneumonia were selected as the research objects and were divided into control group and study group according to the random number table method,36 cases in each group.The control group was treated with Cefoperazone Sulbactam sodium,while the study group was treated with Ambroxol hydrochloride on the basis of that of the control group.The clinical effects,the clinical symptom disappearance time,the inflammatory factor levels[C-reactive protein(CRP),interleukin(IL)-6,IL-10],the pulmonary function index levels[expiratory volume in 1 second(FEV_(1)),FEV_(1)/FVC,forced expiratory flow(FEF75%)]and incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of treatment in the study group was 97.22%,which was higher than the control group of 66.67%,and the difference was statistically significant(P<0.05).After the treatment,the clinical symptom disappearance time such as high fever,cough,expectoration,lung rales and wheezing in the study group was shorter than that in the control group,and the difference was statistically significant(P>0.05).The levels of CRP and IL-6 in the study group were lower than those in the control group,the IL-10 level was higher than that in the control group,and the differences were statistically significant(P<0.05).The levels of FEV_(1),FEV_(1)/FVC and FEF75%in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ambroxol hydrochloride combined with Cefoperazone Sulbactam sodium in the treatment of the patients with severe pneumonia can improve the clinical effects,shorten the clinical symptom disappearance time,reduce the levels of inflammatory factors,and improve the levels of pulmonary function with high safety.Moreover,it is superior to single Cefoperazone Sulbactam sodium.